| Renal Cell Carcinoma
Welireg vs Fotivda
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Welireg vs Fotivda with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFotivda has a higher rate of injection site reactions vs Welireg based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Fotivda but not Welireg, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Welireg
Fotivda
At A Glance
Oral
Once daily
HIF-2α inhibitor
Oral
Once daily
VEGFR tyrosine kinase inhibitor
Indications
- Von Hippel-Lindau Syndrome
- Renal Cell Carcinoma
- Pheochromocytoma
- Paraganglioma
- Renal Cell Carcinoma
Dosing
Von Hippel-Lindau Syndrome Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Renal Cell Carcinoma Adults: 120 mg orally once daily.
Pheochromocytoma Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Paraganglioma Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Renal Cell Carcinoma 1.34 mg orally once daily for 21 days on treatment followed by 7 days off treatment (28-day cycle); reduce to 0.89 mg once daily for moderate hepatic impairment.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) Decreased hemoglobin, fatigue, increased creatinine, headache, dizziness, increased glucose, nausea, musculoskeletal pain, decreased lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium, increased aspartate aminotransferase, anemia, dyspnea, increased calcium, decreased leukocytes, increased alkaline phosphatase.
Serious Anemia, hypoxia, hemorrhage, pneumonia, pleural effusion, pyelonephritis, hypertension, retinal detachment, central retinal vein occlusion, anaphylaxis reaction.
Postmarketing Not reported in label.
Most common (>=20%) fatigue, hypertension, diarrhea, decreased appetite, nausea, dysphonia, hypothyroidism, cough, stomatitis
Serious bleeding, venous thromboembolism, arterial thromboembolism, acute kidney injury, hepatobiliary disorders
Postmarketing gastrointestinal perforation, pancreatitis
Pharmacology
Belzutifan is a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor that binds to HIF-2α and blocks its interaction with HIF-1β, leading to reduced transcription of HIF-2α target genes associated with cellular proliferation, angiogenesis, and tumor growth.
Tivozanib is a tyrosine kinase inhibitor that inhibits phosphorylation of VEGFR-1, VEGFR-2, and VEGFR-3, as well as c-kit and PDGFR-beta, thereby inhibiting angiogenesis, vascular permeability, and tumor growth including human renal cell carcinoma.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Welireg
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Fotivda
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Welireg
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Fotivda
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Welireg
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Fotivda
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Welireg Co-Pay Coupon Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Renal Cell Carcinoma (RCC): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
WeliregView full Welireg profile
FotivdaView full Fotivda profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.